Cancer Patients Treated with Immunotherapy Can Safely Receive mRNA COVID-19 Vaccines, According to JNCCN Study

New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.

Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States

In this population-based surveillance, the authors found that myocarditis/pericarditis 0 to 7 days after mRNA vaccination in persons aged 5 to 39 years occurred in approximately 1 in 200,000 doses after the first dose and 1 in 30,000 doses after second dose of the primary series, and 1 in 50,000 doses after the first booster. The incidence varied markedly by age and sex, however, with a disproportionate number of cases occurring in male persons, notably among adolescents after dose 2 and first boosters.